Back

The association between non-Lp(a)-ApoB / Lp(a) ratio and plaque vulnerability according to lipid oxidation status

29 August 2026 (08:15 - 08:40)
Organised by: Logo
Congress Presentation Part of: Precision cardiology by and beyond optical coherence tomography: integrating imaging, artificial intelligence, and biomarkers for plaque assessment Optical Coherence Tomography ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Taiga Ishigaki

Ishinomaki (Japan)

3 More presentations in this session

Presentation thumbnail
Assessment and contributing factors of adequate endothelization after drug-eluting stent implantation
Doctor M. Nishino (Sakai, JP)
Abstract
Presentation thumbnail
Artificial intelligence-based analysis of stent malapposition and expansion from intracoronary optical coherence tomography
Mr X. Gu (Amsterdam, NL)
Abstract
Presentation thumbnail
A “foundation model” for precision coronary plaque phenotyping: integration of multi-modal imaging, laboratory, and clinical data via contrastive learning
Doctor S. Andreaggi (Boston, US)
Abstract

Access the full session

Session thumbnail
Precision cardiology by and beyond optical coherence tomography: integrating imaging, artificial intelligence, and biomarkers for plaque assessment

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Sex-specific influence of lipoprotein(a) levels on coronary plaque characteristics: the COPRODUCTION-registry
1 September 2025
thumbnail
Congress Presentation
Atorvastatin active metabolite inhibits oxidation of Lp(a), small dense LDL and triglyceride-rich lipoproteins compared to other statins through a free radical scavenging mechanism
29 August 2025
thumbnail
Congress Presentation
Comparing thrombus aspirate pathology with OCT-verified plaque characteristics in acute coronary syndromes
31 August 2025
thumbnail
Congress Presentation
Discordance between LDL cholesterol and apolypoprotein B. Which to prefer to guide treatment?
13 April 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources